Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy

Andrea B. Apolo, Irina Ostrovnya, Susan Halabi, Alexia Iasonos, George K. Philips, Jonathan E. Rosenberg, Jamie Riches, Eric J. Small, Matthew I. Milowsky, Dean F. Bajorin

Manuscript received September 6, 2012; revised December 14, 2012; accepted December 7, 2012.

Correspondence to: Dean F. Bajorin, MD, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065 (e-mail: bajorind@mskcc.org).

A prognostic model that predicts overall survival (OS) for metastatic urothelial cancer (MetUC) patients treated with cisplatin-based chemotherapy was developed, validated, and compared with a commonly used Memorial Sloan-Kettering Cancer Center (MSKCC) risk-score model. Data from 7 protocols that enrolled 308 patients with MetUC were pooled. An external multi-institutional dataset was used to validate the model. The primary measurement of predictive discrimination was Harrell’s c-index, computed with 95% confidence interval (CI). The final model included four pretreatment variables to predict OS: visceral metastases, albumin, performance status, and hemoglobin. The Harrell’s c-index was 0.67 for the four-variable model and 0.64 for the MSKCC risk-score model, with a prediction improvement for OS (the U statistic and its standard deviation were used to calculate the two-sided P = .002).

In the validation cohort, the c-indices for the four-variable and the MSKCC risk-score models were 0.63 (95% CI = 0.56 to 0.69) and 0.58 (95% CI = 0.52 to 0.65), respectively, with superiority of the four-variable model compared with the MSKCC risk-score model for OS (the U statistic and its standard deviation were used to calculate the two-sided P = .02).


A widely used model predicting overall survival (OS) for metastatic urothelial cancer (MetUC) patients treated with cisplatin chemotherapy is based on two prognostic factors—visceral (lung, liver, or bone) metastases and Karnofsky performance status less than 80%—was developed at Memorial Sloan-Kettering Cancer Center (MSKCC) (1). In this analysis of 203 patients with MetUC, median OS for patients with zero, one, or two risk factors were 33, 13.4, and 9.3 months, respectively (P < .001). This model has been validated in two randomized phase III trials of MetUC patients receiving platinum-based therapy (2,3).

The objective of this study was to develop a pretreatment prognostic model that could be used to predict 1-, 2-, and 5-year survival probability and median OS in MetUC patients treated with cisplatin-based chemotherapy and to improve prognostic accuracy over the MSKCC model.

The development dataset for this study included 308 MetUC patients who received cisplatin-based chemotherapy on seven prospective phase II trials with similar inclusion criteria at MSKCC from 1983 to 2003 (Table 1) (1,4–12). All study participants gave written informed consent for participation in the corresponding clinical trial, and the study protocols were approved by the respective institutional review boards.

The primary endpoint was OS, defined as the time from initiation of chemotherapy until death or date of last follow-up. Predictors of OS were considered based on the literature (13–20). Univariate and multivariable analyses used the proportional hazards model for predicting OS; proportional hazards assumption was verified using test for weighted residuals (21). The final model was chosen based on univariate and multivariable P values (statistically significant if ≤.05). All statistical tests were two-sided. The model was internally validated, and its accuracy was assessed using Harrell’s concordance probability, c-index (22). Bootstrap samples (N = 1000) were used to estimate overfitting. The U statistic was used to test whether the predictions of the four-variable model in all possible pairs were more concordant with actual observations than the MSKCC risk-score model in the same pairs. Statistical analyses were performed using R (23) and its Design and Hmisc libraries (24).

The MSKCC risk-score and four-variable models were externally validated by an author (S. Halabi) who was not involved in the development of the prognostic model. The validation cohort, CALGB 90102, included 74 MetUC patients treated with cisplatin, gemcitabine, and gefitinib and enrolled from July 2002 to April 2005 with a median follow-up of 72.3 months (Table 1; Supplementary Figure 1A, available online).

In the nomogram development cohort there was no statistically significant difference in OS among the chemotherapy regimens (doxorubicin, gemcitabine, ifosfamide, paclitaxel, and cisplatin (AGITP) median OS = 16.4, 95% confidence interval [CI] = 14.6 to 22.9; ifosfamide, paclitaxel, and cisplatin (ITP) median OS = 18.0, 95% CI = 12.0 to 29.7; methotrexate, vinblastine, doxorubicin, and cisplatin (M-VP) median OS = 14.8, 95% CI = 12.1 to 16.7; P = .62) (Supplementary Figure 1A, available online). Median survivals by regimen are shown in Table 1. Univariate analyses for predictors of OS included lactate dehydrogenase; albumin, cubic splines using actual values (4 = no additional risk, whereas <4 or >4 = additional risk); hemoglobin, normal vs below normal (below normal for females was <11.5 g/dL and for males was <13 g/dL); Karnofsky performance status, good (≥80)
Male:female 163:40 33:12 46:14 58:16
Median age 63 63 62 64
Median KPS, % 80 80 90
Visceral disease, %
Bone 26 11 10
Liver 13 13 10
Lung 26 22 18
Risk factors, %
0 33 55 62
1 45 41 35
2 22 4 3
Median survival, months (95% CI) 14.8 (12.1 to 16.7) 18 (12.0 to 29.7) 16.4 (14.6 to 22.9) 12.7
Failed/censored, No. 184/19 37/8 53/7 68/6

*AG-ITP = doxorubicin plus gemcitabine followed by ifosfamide, paclitaxel, and cisplatin; CI = confidence interval; GC = gemcitabine and cisplatin; ITP = ifosfamide, paclitaxel, and cisplatin; KPS = Karnofsky performance status; MSKCC = Memorial Sloan-Kettering Cancer Center; MVAC = methotrexate, vinblasticine, doxorubicin, and cisplatin.

**Table 1. Patient characteristics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Nomogram development cohort</th>
<th>Validation cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MSKCC MVAC (n = 203)</td>
<td>MSKCC ITP (n = 45)</td>
</tr>
<tr>
<td>Male:female</td>
<td>163:40</td>
<td>33:12</td>
</tr>
<tr>
<td>Median age</td>
<td>63</td>
<td>63</td>
</tr>
<tr>
<td>Median KPS, %</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>Visceral disease, %</td>
<td>49</td>
<td>40</td>
</tr>
<tr>
<td>Bone</td>
<td>26</td>
<td>11</td>
</tr>
<tr>
<td>Liver</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Lung</td>
<td>26</td>
<td>22</td>
</tr>
<tr>
<td><strong>Risk factors, %</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>33</td>
<td>55</td>
</tr>
<tr>
<td>1</td>
<td>45</td>
<td>41</td>
</tr>
<tr>
<td>2</td>
<td>22</td>
<td>4</td>
</tr>
<tr>
<td>Median survival, months (95% CI)</td>
<td>14.8 (12.1 to 16.7)</td>
<td>18 (12.0 to 29.7)</td>
</tr>
<tr>
<td>Failed/censored, No.</td>
<td>184/19</td>
<td>37/8</td>
</tr>
</tbody>
</table>

The risk variable that takes values 0, 1, and 2 based on Karnofsky performance status (>80) and presence of visceral metastases. This reduced model had a c-index equal to 0.64 (bootstrap corrected = 0.64), which was inferior to the proposed four-variable model (P = .002).

When the nomogram was applied to the validation cohort, the c-indices for the four-variable and MSKCC risk-score models were 0.63 (95% CI = 0.56 to 0.69) and 0.58 (95% CI = 0.52 to 0.65), respectively. Superiority of the four-variable model compared with the MSKCC risk-score model remained (P = .02).

This study reports and validates a prognostic model for predicting survival probabilities at 1-, 2-, and 5-year survival and bias the estimated treatment benefit. Pretreatment stratification with this four-variable prognostic model in prospective phase II or III trials in MetUC patients could ensure similarity of cohorts for comparison and reduce the likelihood that survival differences are a function of patient characteristics. The prognostic model may also be used for comparing OS results across phase II trials.

There are multiple strengths of the four-variable model compared with the MSKCC risk-score model beyond statistical superiority. This model incorporates a larger number of MetUC patients from seven protocols. The model was also validated externally using a cooperative group trial.

There are limitations to the four-variable model. First, the patients participated in clinical trials, and there is the potential that the model may not be predictive for patients ineligible for protocol therapy. Moreover, it has yet to be validated in non-cisplatin-treated patients. Second, the model did not include factors such as histology or molecular markers that may influence survival (30–37). Lastly, the 5-year survival in patients with MetUC is less than 10%; therefore, the robustness of the model’s 5-year survival prediction is low. Despite these limitations, the model can be used clinically, and this methodology lends itself well for refinement as other prognostic factors are identified in the future.
Figure 1. Nomogram for predicting survival of patients with metastatic or unresectable urothelial cancer treated with cisplatin chemotherapy. To estimate survival, calculate points for each predictor by drawing a straight line from patient’s value to the axis labeled “Points.” Add all points, and draw a straight line from the total point axis to the 1-year, 2-year, 5-year, or median survival (months) axis. ALB = albumin; Hgb = hemoglobin; KPS = Karnofsky performance status.

References

Funding
This work was supported by a National Institutes of Health Training Grant (T-32CA09207) and the Zena and Michael A. Wiener Research and Therapeutic Program in Bladder Cancer.

Notes
The study sponsors did not have a role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. The authors have no conflicts of interest.

The developed nomogram was initially presented at the 2007 ASCO Annual Meeting poster discussion session in Genitourinary Cancer (J Clin Oncol. 2007;25(18S):3055). The validation of the
nomogram was presented at the 2012 ASCO Annual Meeting general poster session in genitourinary cancer (J Clin Oncol. 2012;30(suppl):abstract 4592).

Affiliations of authors: Genitourinary Oncology Service, Department of Medicine (ABA, JER, JR, MIM, DFB) and Department of Epidemiology and Biostatistics (IO, AI), Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY (ABA, JER, JR, MIM, DFB); Department of Biostatistics and Bioinformatics and Alliance Statistical Center, Duke University Medical Center, Durham, NC (SH); Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC (GKP); Comprehensive Cancer Center, University of California–San Francisco, San Francisco, CA (EJS).